Clinical Trials Logo

Hemophilia A clinical trials

View clinical trials related to Hemophilia A.

Filter by:

NCT ID: NCT00189982 Completed - Hemophilia A Clinical Trials

Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101

Start date: December 17, 2004
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of children with hemophilia A. The study is open to pediatric patients in Canada who completed Baxter Study 060101.

NCT ID: NCT00178607 Recruiting - Hemophilia A Clinical Trials

Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia

Start date: August 2002
Phase: N/A
Study type: Observational

To correlate the Human Leukocyte Antigen type and genetic defect with hemophilia A.

NCT ID: NCT00168090 Completed - Clinical trials for Blood Coagulation Disorders

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

Start date: October 2001
Phase: Phase 4
Study type: Interventional

The purpose of this study is to test the safety and effectiveness of Humate-P® to prevent bleeding in patients with von Willebrand Disease who are undergoing surgery.

NCT ID: NCT00168051 Withdrawn - Hemophilia A Clinical Trials

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

Start date: April 2005
Phase: Phase 4
Study type: Interventional

The purpose of the study is to compare the pharmacokinetic parameters of ReFacto and Advate, using the chromogenetic substrate assay to measure plasma Factor VIII activity in plasma.

NCT ID: NCT00167973 Completed - Hemophilia B Clinical Trials

Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use

Start date: January 2002
Phase: Phase 4
Study type: Observational

This is an open-label multi-center Registry in patients with hemophilia B receiving BeneFIX. All patients who begin treatment with BeneFIX in European Union countries, will be eligible for participation. Patient demographics will be collected at baseline for all patients. A baseline FIX activity and Bethesda assay for inhibitor based on historical data should be recorded if available. Adverse events as defined in the protocol will also be reported on the appropriate forms. Data will be collected from patients on an ongoing basis to ensure that information is being captured for each patient being treated with BeneFIX.

NCT ID: NCT00166387 Completed - Clinical trials for Hemophilia A With Inhibitor

Hemophilia Inhibitor Genetics Study (HIGS)

Start date: April 2003
Phase: N/A
Study type: Observational

Several non-genetic and genetic factors that could influence the risk of inhibitor development in hemophilia A have been discussed but not fully explored. The aim of the HIGS is to identify these genetic factors.

NCT ID: NCT00166309 Completed - Clinical trials for Severe Hemophilia A With an Inhibitor

The FEIBA NovoSeven Comparative Study

Start date: July 2000
Phase: N/A
Study type: Interventional

FENOC is a prospective, open-label, randomized, cross-over, multi-center study to investigate and compare the hemostatic effect and cost-efficacy of two different by-passing agents in the treatment of joint hemorrhages in subjects with severe hemophilia A and inhibitors. The study is designed as a clinical equivalency trial.

NCT ID: NCT00162019 Completed - Hemophilia A Clinical Trials

Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients

Start date: March 31, 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether IMMUNATE S/D is effective and safe in the treatment of hemophilia A patients. The study consists of 3 parts: Part 1 is a pharmacokinetic comparison of IMMUNATE S/D and its predecessor IMMUNATE. Part 2 is an evaluation of efficacy and safety of IMMUNATE S/D. Part 3 is a pharmacokinetic study of IMMUNATE S/D.

NCT ID: NCT00157157 Completed - Hemophilia A Clinical Trials

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

Start date: April 1, 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM) is effective and safe in the treatment of hemophilia A patients who have not been treated with factor VIII (FVIII) before.

NCT ID: NCT00157105 Completed - Hemophilia A Clinical Trials

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

Start date: February 12, 2001
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A patients undergoing surgery.